mifepristone has been researched along with Carcinoma, Ductal, Pancreatic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellini, R; Biagioli, M; Bordoni, M; Catalanotti, B; Di Giorgio, C; Distrutti, E; Fiorucci, S; Lupia, A; Marchianò, S; Massa, C; Monti, MC; Moraca, F; Morretta, E; Roselli, R; Sepe, V; Urbani, G; Zampella, A | 1 |
| Fabri, PJ; Godellas, CV; Gower, WR; Risch, RM | 1 |
2 other study(ies) available for mifepristone and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Drug Repositioning; Female; Hormone Antagonists; Humans; Mifepristone; Pancreatic Neoplasms; Pregnancy; Receptors, OSM-LIF | 2022 |
HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Dose-Response Relationship, Drug; Hormone Antagonists; Humans; Hydrocortisone; Insulin; Karyotype; Male; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Pancreatic Neoplasms; Receptors, Glucocorticoid; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays | 1994 |